Corticosteroid and endocannabinoid actions converge on prefrontocortical circuits associated with neuropsychiatric illnesses. Corticosteroids can also modulate forebrain synapses by using endocannabinoid effector systems. Here, we determined whether corticosteroids can modulate transmitter release directly in the frontal cortex and, in doing so, whether they affect presynaptic CB 1 cannabinoid receptor-(CB 1 R) mediated neuromodulation. By Western blotting of purified subcellular fractions of the rat frontal cortex, we found glucocorticoid receptors (GcRs) and CB 1 Rs enriched in isolated frontocortical nerve terminals (synaptosomes). CB 1 Rs were predominantly presynaptically located while GcRs showed preference for the post-synaptic fraction. Additional confocal microscopy analysis of cortical and hippocampal regions revealed vesicular GABA transporter-positive and vesicular glutamate transporter 1-positive nerve terminals endowed with CB 1 R immunoreactivity, apposing GcR-positive post-synaptic compartments. In functional transmitter release assay, corticosteroids, corticosterone (0.1e10 microM) and dexamethasone (0.1e10 microM) did not significantly affect the evoked release of [ corticosteroids are unlikely to exert direct non-genomic presynaptic neuromodulation in the frontal cortex, but they may do so indirectly, via the stimulation of trans-synaptic endocannabinoid signaling.
Introduction
Corticosteroids produce diverse responses in various classes of neurons and astrocytes in the brain (Chaouloff and Groc, 2011; Jo€ els et al., 2012; Maggio and Segal, 2012; Yu et al., 2011) . Alternative splicing and post-translation modifications yield pharmacologically and structurally distinct subtypes of corticosteroid-sensing mineralocorticoid and glucocorticoid receptors (McR and GcR). These receptors can either mediate slow genomic responses when located intracellularly or, they can directly control other receptors, membrane conductance, release probability and synaptic plasticity when inserted in the plasmalemma (Chaouloff and Groc, 2011; Chen et al., 2012; Jo€ els et al., 2012; Maggio and Segal, 2012; Tse et al., 2011) . Only a few of these responses were associated with presynaptic loci, probably because non-genomic corticosteroid modulation of ionic currents at the second to minute scale is less typical (Jo€ els et al., 2012; Zaki and Barrett-Jolley, 2002) . The particular mechanism(s) leading to rapid presynaptic neuromodulation by corticosteroids has not been fully elucidated, and the underlying receptor has been ascribed either as McR (Jo€ els et al., 2012; Karst et al., 2005; Maggio and Segal, 2012) or as GcR .
Corticosteroids alone are often insufficient to increase presynaptic neurotransmitter release: acute stress rapidly raises the readily releasable pool of glutamate in the rat (pre)frontal cortex, and augments its depolarization-induced ex vivo release (Popoli et al., 2011) . However, corticosterone applied in vitro onto isolated nerve terminals (synaptosomes) does not affect glutamate release per se (Treccani et al., 2014) .
In the prefrontal cortex (PFC), acute stimulation of glutamate release by corticosteroids under stressful stimuli is among the first steps to terminate the stress response via a feed-back loop feeding into the hypothalamo-pituitary-adrenal (HPA) axis (Herman et al., 1996; Jo€ els et al., 2012) . Chronic stress, however, can impair the delicate context of neuromodulation in the PFC, which can elicit numerous neuropsychiatric illnesses (Opris and Casanova, 2014) , including impaired fear extinction (Bitencourt et al., 2013) . We recently found that GcRs rather than McRs facilitate prefrontal cortex-dependent conditioned fear extinction by promoting endocannabinoid signaling at CB 1 cannabinoid receptors (CB 1 Rs) (Bitencourt et al., 2014) . G i/o protein-coupled metabotropic CB 1 Rs are expressed at high density in subsets of GABA-ergic interneurons, while their expression at lower density is typical for many pyramidal cells throughout the neocortex, with predominant axonal (presynaptic) localization (Egertov a and Elphick, 2000; Hill et al., 2007; Marsicano and Lutz, 1999; Tsou et al., 1998 ). An additional CB 1 R paralogue, the CB 2 cannabinoid receptor (CB 2 R) is largely expressed peripherally with circumstantial evidence inferring central roles (Zhang et al., 2015) .
CB 1 Rs serve as downstream mediators of glucocorticoid action in frontocortical and hippocampal areas. CB 1 Rs control the feedback loop along the HPA axis to terminate stress responses (Hill et al., 2011; Hill and Tasker, 2012) , as well as to facilitate the extinction and impair the retrieval of aversive memories (Atsak et al., 2012; Bitencourt et al., 2013 Bitencourt et al., , 2014 Hill et al., 2011; Marsicano et al., 2002) . Due to these important roles, endocannabinoids (endogenous CB 1 R agonists) have been implicated in the pathogenesis of chronic stress-related psychiatric illnesses (Bitencourt et al., 2013; K€ ofalvi and Fritzsche, 2008; Trezza and Campolongo, 2013) .
Prompted by the lack of conclusive evidence on a signaling interplay between GcRs and CB 1 Rs, we aimed at mapping the acute presynaptic effects of corticosteroids on the resting and depolarization-evoked release of radiolabeled GABA and glutamate in superfused synaptosomes of the frontal cortex of laboratory rodents, which is a model free from polysynaptic and glial influences (Popoli et al., 2011) . We also asked whether corticosteroids could modulate the presynaptic CB 1 R activity in relation to the evoked release of GABA and glutamate.
Materials and methods

Ethics statement and animals
All studies were conducted in accordance with the principles and procedures outlined as "3Rs" in the guidelines of EU (86/609/ EEC), FELASA, and the National Centre for the 3Rs (the ARRIVE; Kilkenny et al., 2010) , and were approved by the Animal Care Committee of the Center for Neuroscience and Cell Biology of the University of Coimbra, Portugal. We also applied the ARRIVE guideline for the design and execution of in vitro pharmacological experiments (see below), as well as for data management and interpretation (McGrath et al., 2010) .
In specific detail, 90 male Wistar rats (180e240 g, 8e10-week old) were purchased from Charles-River (Barcelona, Spain). Six CB 1 receptor null-mutant (knockout, KO) male mice with a CD-1 background (Ledent et al., 1999) and six of their wild-type littermates (35e45 g, 8e12-week old) were also used in pharmacological experiments. Animals were housed with 12 h light on/off cycles under controlled temperature (23 ± 2 C), and ad libitum access to food and water. All efforts were made to minimize the number of animals used and to minimize their stress and discomfort. Animals used in vitro studies were deeply anesthetized with halothane before (5%, 1 L/min flow rate) before cervical dislocation.
Subcellular fractionation and Western blotting
After decapitation, rat brains were rapidly collected in ice-cold Krebs-HEPES assay solution (in mM: NaCl 113, KCl 3, KH 2 PO 4 1.2, MgSO 4 1.2, CaCl 2 2.5, NaHCO 3 25, glucose 5.5, HEPES 10), and frontal cortices were dissected (Paxinos and Watson, 1998) . Frontal cortices were used instead of the much smaller prefrontal cortex to obtain sufficient amount of protein. To test the presence of GcR in frontocortical nerve terminals, we prepared a purified synaptosome (nerve terminal) fraction from three rats, following Dunkley et al. (2008) . As Fig. 1A and E demonstrate, brain membrane fractions contain high densities of PSD95 -a membrane-bound marker of post-synapses (Ehlers et al., 1996) , whereas this marker is largely diluted in crude (total) brain homogenate by the copious amounts of intracellular proteins, and was largely absent in the purified synaptosomes. To support the specificity of the anti-GcR antibody available to us (Abcam), we tested for GcR translocation from cytoplasmic to nuclear fractions upon its stimulation with dexamethasone (Sarabdjitsingh et al., 2010) (Fig. 1AeA 1 ) . In brief, frontal cortices from three animals were cut on a McIlwain tissue chopper (450 mm-thick coronal slices). These slices were divided in two pools per animal, and incubated in 50 mL Krebs-HEPES buffer, and constantly gassed with 5% CO 2 , 95% O 2 for 1 h at 37 C. Next, one pool from each animal was treated with dexamethasone (10 mM), while the other sample was exposed to DMSO (vehicle control, 0.1%) for 30 min under 37 C. After incubation, the slices were collected, and their cytoplasmic vs. nuclear fractions were separated according to Guillemin et al. (2005) .
Quantitative Western blotting with total protein normalization
Protein samples were homogenized by sonication in TNE buffer (50 mM TriseHCl, 100 mM NaCl, 0.1 mM EDTA, pH 7.4) containing 0.5% Triton X-100 (Sigma), 1% octyl-b-D-glucopyranoside (Calbiochem), 5 mM NaF, 100 mM Na 3 VO 4 and a cocktail of protease inhibitors (Complete™, Roche). Protein concentrations were determined by Bradford's colorimetric method (Bradford, 1976) . Aliquots of rat synaptosome and tissue-specific control lysates containing: 10 mg protein in 20 mL (for synaptophysin and PSD95 detection) or 20 mg protein in 40 mL (GcR, CB 1 R) were used. Total protein labeling was initiated by adding Cy5 dye reagent (GE Healthcare) that had been pre-diluted (1:10) in ultrapure water. Samples were mixed and incubated for 30 min at 22e24 C. The labeling reaction was terminated by adding Amersham WB loading buffer (GE Healthcare; 20 mL/sample) containing 40 mM dithiothreitol. Samples were then heated at 95 C for 3 min. Forty mL of each sample was loaded onto an Amersham WB gel card-14 (13.5% gel). Electrophoresis (600 V, 45 min) and protein transfer onto polyvinylidine-difluoride membranes (100 V, 30 min) were at default settings in an integrated Amersham WB system (GE Healthcare) for quantitative SDS-PAGE and Western blotting of proteins with fluorescence detection. Protein samples on membranes were incubated at 4 C overnight with one of the following primary antibodies: mouse anti-GcR (BuGR2, mouse, monoclonal, 1:500; Abcam), guinea pig anti-CB 1 R (1:500; kind gift of Dr.
Masahiko Watanabe), mouse b-actin (monoclonal; 1:10,000; Sigma), rabbit anti-synaptophysin (1:1000; Synaptic Systems) and rabbit anti-post-synaptic density protein 95 (polyclonal; PSD95; 1:500, Synaptic Systems). To demonstrate the specificity of the guinea pig anti-CB 1 R antibody, we prepared cerebellar homogenates from wild-type (WT) mice and their CB 1 R KO littermates. We found specific bands at the expected molecular weight (~53 kDa) in the WT mice as well as in the purified synaptosomes but not in the CB 1 R KO mice (Fig. 1C) .
Antibody binding was detected by using species-specific (antirabbit, anti-mouse and anti-guinea pig) carbocyanin (Cy)3-labeled secondary antibodies (1:1000; GE Healthcare). Membranes were dried before scanning at 560 nm (Cy3) and 630 nm (Cy5) excitation. Automated image analysis was performed in the Amersham WB evaluation software, and optimized by manual editing.
Tissue processing and histochemistry
Rats were transcardially perfused under deep pentobarbital anesthesia (50 mg/kg) with a fixative containing 4% paraformaldehyde (PFA) and 0.1% glutaraldehyde in 0.1 M phosphatebuffer (PB, pH 7.4), post-fixed in PFA overnight, and subsequently cryoprotected in 30% sucrose (in PB). Brains were sectioned coronally (50 mm thickness) on a Leica CM1850 cryostat microtome.
Free-floating sections were rinsed in PB and pre-treated with 0.3% Triton-X 100 (Sigma, in PB) for 1 h at 22e24 C to enhance the penetration of antibodies. Non-specific immunoreactivity was suppressed by incubating our specimens in a cocktail of 5% normal donkey serum (Jackson), 1% bovine serum albumin (BSA, Sigma) and 0.3% Triton X-100 in PB for an additional hour at 22e24 C. Sections were then exposed to select combinations of primary antibodies: mouse anti-GcR (BuGR2, 1:500, Abcam) (Sarabdjitsingh et al., 2010) , rabbit anti-VGLUT1 (1:2000; Synaptic Systems) (Kaneko et al., 2002) , rabbit anti-VGAT (1:1,000, Synaptic Systems) (Martens et al., 2008) ; goat anti-CB 1 R (1:1000; Frontier-Science) (Kawamura et al., 2006) and guinea pig anti-DAGLa (1:500; gift of Dr. K. Mackie) (Keimpema et al., 2013) ; diluted in PB (48e72 h at 4 C) to which 0.5% normal donkey serum and 0.3% Triton X-100 had been added. After extensive rinsing in PB, immunoreactivities were revealed by carbocyanine (Cy) 2, 3 or 5-tagged secondary immunoreactivity, suggesting that the target band might confer to GcR. (BeE) Qualitative multiplex Western blotting of total proteins pre-labeled by Cy5 fluorophore and individual targets detected by Cy3-labeled secondary antibodies. Total protein labeling served as loading control, and was also used to exclude unwanted protein degradation during synaptosome preparation. Both glucocorticoid receptors (B) and CB 1 cannabinoid receptors CB 1 Rs (C) were detected in lysates of rat synaptosome fractions. Cerebellar membranes from adult CB 1 R knockout (KO) and wild-type mice were used to control the specificity of the guinea pig anti-CB 1 R antibody (~53 kDa). (D) Synaptophysin (SYN,~35 kDa) and (E) postsynaptic density protein (PSD95) were immunoblotted to show increased presynaptic abundance in the purified synaptosome preparations. For PSD95, total protein lysates, as well as membrane fractions (both from adult mouse cortex) were included. In all cases, three synaptosome samples (isolated independently from three rat frontal cortices) were run in parallel. *P < 0.05 (Student's t-test).
antibodies raised in donkey (1:200 (Jackson), at 22e24 C, 2 h). Lipofuscin autofluorescence was routinely quenched by applying Sudan Black-B (1%, dissolved in 70% ethanol) (Schnell et al., 1999) . Glass-mounted sections were coverslipped with Aquamount (Dako, Glosstrup, Denmark). Images acquired on a 700LSM confocal laserscanning microscope (Zeiss). Image surveys were generated using the tile-scan function with optical zoom ranging from 0.6 Â to 1.5 Â at 10 Â primary magnification (objective: EC Plan-Neofluar 10 Â /0.30). Co-localization was defined as immunosignals being present without physical signal separation in 0.5e0.7-mm optical slices at 40Â (Plan-Neofluar 40 Â /1.30) or 63 Â (Plan-Apochromat 63 Â /1.40) primary magnification and at optical zoom ranging from 1e3 Â . Emission spectra for each dye were limited as follows: Cy2 (505e530 nm), Cy3 (560e610 nm), and Cy5 (650e720 nm). Multipanel figures were assembled in CorelDraw X5 (Corel Corp.).
CB 1 R and GcR distribution in the pre-and post-synapse
Preparation of pre-and post-synapse-enriched synaptosomal fractions from the cerebral cortex of male Wistar rats (n ¼ 3) was performed as described (Hahn et al., 2009; Phillips et al., 2001) . We used a quantitative proteomic approach to determine CB 1 R and GcR levels at subcellular fractions. Briefly, 50 mg protein was digested by trypsin (1:100 w/w%) using a filter-aided sample preparation protocol (Manza et al., 2005; Wisniewski et al., 2009 ). In the three biological replicates, the pre-and post-synaptic protein fractions were labeled using TMT 6-plex reagents (channels 126e128 and 129e131, respectively; ThermoFisher Scientific), according to the manufacturer's instructions. Then, samples were pooled and fractionated by reversed-phase liquid chromatography (Gilar et al., 2005) . Fractions were analyzed by nanoscale liquid chromatography coupled to tandem mass spectrometry (nano-LC-MS/MS; Bennett et al., 2011) . Proteins were identified by matching nano-LC-MS/MS results against a SwissProt database for rat (version 2013.01; 9626 sequences). Relative protein abundance for each sample was derived from the TMT reporter ion identities.
Data were expressed as means ± S.E.M. of the ratio of pre-and post-synaptic receptor quantities (i.e. equal amount of receptors at the two sites corresponds to 1). Student's t-test was used to evaluate statistical differences.
Dual-label [ 3 H]GABA/[
14 C]glutamate release assay from cortical nerve terminals and ex vivo brain slices Experiments were carried out as described (Ferreira et al., 2012; K€ ofalvi et al., 2007) , with slight modifications. Briefly, frontal cortices were rapidly dissected (as the small size of the prefrontal cortex did no allow the isolation of sufficiently high quantity of synaptosomes) in 2 mL of ice-cold sucrose solution (0.32 M, containing 5 mM HEPES, pH 7.4). After homogenization with a Teflon homogenizer, and centrifugation at 3000 g for 5 min, the supernatant was collected and centrifuged at 13,000 g for 10 min to obtain the P2 synaptosomal fraction.
Synaptosomes -isolated nerve terminals (Whittaker et al., 1964) , represent a preferred tool to study presynaptic processes free of polysynaptic and glial influences (Popoli et al., 2011; Raiteri and Raiteri, 2000) . Synaptosomes (in 0.5 mL) were thus simultaneously incubated (loaded) continuously at a rate of 0.8 mL/min with Krebs-HEPES solution (37 C) until the end of the experiments. Upon termination of a 10-min washout and after collecting three 2-min samples as baseline, neurotransmitter release was stimulated twice (S 1 , S 2 ) with 10-min intervals (except where stated otherwise), and with identical stimuli, ranging from 10 to 75 mM K þ or 1 mM 4-aminopyridine (4-AP). Evoked neurotransmitter release was largely Ca 2þ -dependent and subject to neuromodulation exclusively by presynaptic receptors (Raiteri and Raiteri, 2000) . The intrachamber S 2 /S 1 ratio served to evaluate the effect of drug treatments. Experiments were performed in duplicate. Upon bath application of any substance in the superfusion solution, it remained present until the end of the experiment (that is, there was no washout study). Corticosteroid agonists, corticosterone (0.1e10 mM) and dexamethasone (0.1e10 mM) and the glucocorticoid antagonist, mifepristone, or their vehicle, DMSO were added 4-min before S 2 . In a subset of experiments, the interstimulus interval was increased to 20 min, and corticosterone (10 mM) and dexamethasone (10 mM) or their vehicle, DMSO were present for 15 min before S 2 . The CB 1 R-selective neutral antagonist, O-2050 (1 mM), the CB 1 R-selective inverse agonist, rimonabant (1 mM) and the CB 2 R-selective inverse agonists, AM630 (1 mM) and JTE907 were added 16 min before S 1 , from the beginning of the preperfusion period. The mixed CB 1 R/CB 2 R agonist WIN55212-2 (1 mM) and the CB 2 R-selective agonists, GP1a (100 nM) and JWH133 (0.3 and 3 mM) or their vehicle, DMSO (0.1%) were added to the superfusion medium 4-min before S 2 . The concentration of 1 mM for the cannabinoid ligands was chosen as the maximal cannabinoid receptorselective ligand concentration (see e.g. K€ ofalvi et al., 2003, 2007) .
The 
Data presentation
All data represent means ± S.E.M. of "n" observations (animals) in duplicates (release experiments) or triplicates (quantitative Western blotting). Raw effect data (S 2 /S 1 ratio) on neurotransmitter release were normalized to the S 2 /S 1 ratio of the DMSO control, measured from the same animal. Due to the small effect amplitudes, some bar graphs represent data as % change in the S 2 /S 1 ratio upon treatment as compared to DMSO S 2 /S 1 ratio, which was taken as 100%. Baseline effect of treatments was compared to the appropriate control baseline levels in the presence of DMSO vehicle at a given time point, and expressed as a % change as above. The principle of effect size calculations was reported earlier by Garção et al. (2013) . Normalized data were tested for normal distribution by the KolmogoroveSmirnov test. Statistical significance was determined using with Student's paired t-test. One-way ANOVA followed by Dunett's post-hoc test or by one-sample t-test against the hypothetical value of 100 (%) for the rest of the data, and P < 0.05 was accepted for significant difference. Tests were performed using the GraphPad Prism 5.0 software package.
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Results
Glucocorticoid and CB 1 receptors are present in frontocortical presynapses
First, we asked if GcRs and CB 1 Rs are present presynaptically, which would support their ability of direct presynaptic neuromodulation. As Fig. 1 illustrates, specific immunoreactivities for both GcRs and CB 1 Rs were present in purified nerve terminals (synaptosomes). Purified synaptosomes were rich in synaptophysin, a presynaptic marker (Rehm et al., 1986) (Fig. 1D) , while PSD95, a major membrane-bound post-synaptic marker (Ehlers et al., 1996) was relatively modestly detected (Fig. 1E) . In the absence of GcR knock-out mice, we tested the specificity of the GcR antibody as follows: dexamethasone treatment is expected to increase the nuclear transport of the GcR (Sarabdjitsingh et al., 2010) , hence we divided acute frontocortical slices of three rats, and treated them with either dexamethasone (10 mM) or its vehicle, DMSO, and subsequently, we isolated cytoplasmic and nuclear proteins for Western blotting. Thirty min treatment with dexamethasone triggered nuclear import of the GcR, which was represented by a more than two-fold increase in the~96 kDa band in the nuclear fraction, while a decrease in the density of the same band was observed in the cytoplasmic fraction (Fig. 1A,A' ).
GcR localization in relation to CB 1 R and DAGLa in rat cerebral cortex
First, we asked whether the subcellular localization of GcRs and CB 1 Rs allows for their direct interaction in the cerebral cortex. By multiple-label histochemistry, GcRs were predominantly localized to the perikarya of cortical neurons ( Fig. 2A) . In contrast, CB 1 Rs were chiefly positioned presynaptically, as suggested by their overlapping distribution with VGLUT1 ( Fig. 2A 1 ,A 2 ) . Highresolution laser-scanning microscopy revealed CB 1 R þ /VGAT þ terminals apposing GcR-laden neuronal somata and proximal dendrites in, e.g., the prefrontal cortex (Fig. 2B,B 1 ). We then extended these observations to the hippocampal formation. We took advantage of high levels of CB 1 Rs in glutamatergic terminals in the inner molecular layer of the dentate gyrus (Monory et al., 2006) to show dendritic GcR-like labeling in processes receiving dense (Fig. 2CeC 3 ) . We further extended these data to CA1 pyramidal neurons ( Fig. 2DeD 4 ) by demonstrating the somatic and dendritic co-existence of GcRs and diacylglycerol lipase a (DAGLa), a post-synaptic enzyme synthesizing 2-AG (Reisenberg et al., 2012; . Next, we sought independent verification of these histochemical findings by probing pre-and post-synaptic subcellular fractions for GcR and CB 1 Rs. Our analysis confirmed the predominance of CB 1 Rs in the presynapse. In contrast, GcRs were chiefly enriched in the postsynaptic fraction (Fig. 2E ).
3.3. Optimization of the synaptosomal transmitter release assay to study presynaptic neuromodulation To achieve optimal signal-to-noise ratio in the receptormediated modulation of evoked transmitter release, one needs to balance between the stimulus strength and the treatment effect amplitude (del Carmen Godino et al., 2007 (n ¼ 3, P > 0.05) (Fig. 3F) , thus negating the usefulness of this form of stimulus for our present aims.
Corticosteroids do not have robust presynaptic neuromodulator action in the frontal cortex and the hippocampus
Next, we tested the corticosteroid agonists, dexamethasone and corticosterone on a high number of animals to allow reliable detection of presynaptic neuromodulation even in the case of small effect amplitudes. The release diagrams with dexamethasone (10 mM) -treatment under different stimulation paradigms in rats and mice are included in Fig. 3AeD Supplementary Fig. 1A,B) . Similarly, dexamethasone (10 mM) did not affect the release of [ The corticosteroid agonists, either after 4 min or after 15 min, also did not change the resting outflow of the two neurotransmitters, which process is in part Ca 2þ -dependent, but mostly Na þ -dependent and transporter-mediated (Figs. 5B and 6B). The only exception was that after 4 min of perfusion, 1 mM dexamethasone produced a small (5.5%) but significant increase in the resting glutamate outflow (n ¼ 10, P < 0.05) (Fig. 6B) . Next, we asked if by any chance the presynaptic GcRs were under constitutive activity which could mask any effect for dexamethasone. We thus tested mifepristone on the S 2 /S 1 ratio of both transmitters. Mifepristone is a potent GcR antagonist with K d < 1 nM (Baulieu, 1989) . Mifepristone, at the concentration of 100 nM which is enough to completely block GcRs did not affect either the resting or the evoked release of both transmitters ( Supplementary Figs. 2,3 ), suggesting the lack of endogenous GcR activity in our system, which is indeed what one expects in superfused synaptosomes. In the low micromolar range however, mifepristone strongly depressed both the resting and the 15 mM K þ -evoked release of both transmitters, which was not prevented by the co-administration of dexamethasone at high concentrations (10 and 30 mM) (Supplementary Figs. 2,3 ). This serves as an additional proof of that mifepristone's action is unrelated to an antagonism at putative constitutively active GcRs. To further investigate the underlying mechanisms of mifepristone's action is beyond the scope of this study, but additional discussion can be found in the Supplementary Material.
Pharmacological characterization of presynaptic cannabinoid action
WIN55212-2 is a potent, non-selective agonist of both the CB 1 R and the CB 2 R (Pertwee et al., 2010) . The CB 1 R-selective neutral antagonist, O-2050 (1 mM) (Pertwee et al., 2010) . Therefore, we retested WIN55212-2 in the presence of the CB 2 R-selective inverse agonist, JTE907 (1 mM). CB 2 R blockade did not significantly affect the inhibitory action of WIN55212-2 on the evoked release of either neurotransmitter (n ¼ 4, P > 0.05 between WIN55212-2 vs. WIN55212-2 þ JTE907 combined) (Fig. 7A,B) . For curiosity, we also tested the CB 2 R-selective agonists, GP1a (100 nM) (Murineddu et al., 2006) and JWH133 (0.3 and 3 mM) (Huffman et al., 1999) and both of them were devoid of effect on either the resting or the evoked transmitter releases (n ¼ 4e6; P > 0.05 vs. DMSO control) (Fig. 7A,B) . Additional pharmacological characterizations of the sensitivity of the effect of WIN55212-2 to the CB 1 R inverse agonist, rimonabant and the CB 2 R inverse agonist, AM630 have been carried out as illustrated by Supplementary Fig. 4 . However these data suggest maintaining a cautious approach on relying on rimonabant and AM630 in similar assays.
Finally, to confirm the role of the CB 1 R, we assayed WIN55212-2 in frontocortical synaptosomes isolated from both the CB 1 R KO mice and their WT littermate mice. WIN55212-2 inhibited the evoked release of [ 3 H]GABA and of [ 14 C]glutamate in WT mice (n ¼ 6, P < 0.05 between WIN55212-2 and DMSO; Fig. 7A,B) , but not in the CB 1 R KO littermates (n ¼ 6, P > 0.05 between WIN55212-2 and DMSO; Fig. 7A,B) . The tendency of WIN55212-2 to decrease the evoked release of [ 14 C]glutamate in the CB 1 R KO mice has been previously observed and is probably related to either a direct Ca 2þ channel antagonism (which was still not significant at 1 mM of this cannabinoid (K€ ofalvi et al., 2007) ) or a putative developmental compensation by CB 2 Rs in glutamatergic terminals.
Corticosteroids do not affect presynaptically the neuromodulator action of the CB 1 R in the frontal cortex
Next we asked if glucocorticoids could interfere with the presynaptic neuromodulator role of CB 1 Rs. Hence, we coadministered WIN55212-2 (1 mM) with corticosteroid agonists.
The amplitude of inhibition by WIN55212-2 was not significantly altered either by corticosterone (10 mM; n ¼ 7, P > 0.05 for both neurotransmitters) or by dexamethasone (10 mM; n ¼ 11, P > 0.05 for both neurotransmitters) (Fig. 8A,B (Fig. 8A,B) .
Discussion
While acute stress increases fitness and therefore is benign, chronic elevation of plasma corticosteroid levels can trigger neurological and psychiatric illnesses, including memory loss, hypoplasticity, depression, post-traumatic stress disorder and neurodegeneration (Bitencourt et al., 2013; Detka et al., 2013; Jo€ els et al., 2012; Mora et al., 2012) . As our knowledge on subacute (genomic) and/or post-synaptic modulation of synaptic plasticity by corticosteroids is greatly expanding (Jo€ els et al., 2012; Maggio and Segal, 2012; Sebastian et al., 2013) , we asked now if corticosteroids can also serve as fast direct presynaptic neuromodulators, either on their own or involving the CB 1 cannabinoid receptor (CB 1 R).
An important conclusion of this study is that glucocorticoid receptors (GcRs) are present at the frontocortical presynapse at low density. Moreover, the subsynaptic mapping of the two receptors revealed post-synaptic preference for GcRs and predominantly presynaptic location for CB 1 Rs in the cerebral cortex. Also, VGAT þ nerve endings in the prefrontal cortex and VGLUT1 þ terminals in the hippocampus were found to face apposing post-synaptic compartments rich in GcRs. An additional staining revealed that immunoreactivity for DAGLa, a major enzyme that produce the endocannabinoid, 2-arachydonoylglycerol brain (Reisenberg et al., 2012; , is adjacent to GcR immunoreactivity. These all suggest a complex trans-synaptic interaction between corticosteroids and the endocannabinoid system. But according to the preferentially post-synaptic distribution of GcRs, we did not find corticosteroids to exert robust rapid presynaptic modulation of either the resting or the depolarizationevoked release of GABA and glutamate in isolated presynapses. To Note that all four panels display the mean ± S.E.M. of experiments with the synthetic cannabinoid, WIN55212-2 (1 mM; blue triangles), and the glucocorticoid, dexamethasone (10 mM; orange downward triangles) as well as their vehicle control, DMSO (0.1% control; red circles). All substances were administered in the superfusion medium according to the horizontal bar. FR%, fractional release %, i.e. the release value relative to the total synaptosomal content at any given time-point. (E) The comparison of the amplitudes of the [ directly modulate transmitter release on a second to minute timescale, presynaptic receptors should be linked with voltage-gated Ca 2þ channels (VGCCs) and/or K þ channels (Jong and Fioravante, 2014; Kim and Hoffman, 2008) . The CB 1 R has been shown to operate via both the inactivation of VGCCs and the activation of outward K þ currents . In contrast, corticosteroid receptors are known as indirect modulators of VGCCs via genomic mechanisms in the limbic system, rather than fast regulators of Ca 2þ signaling (Jo€ els and Karst, 2012) . This would likely preclude the modulation of Ca 2þ -dependent evoked release by both GcRs and mineralocorticoid receptors (McRs) in the synaptosomes, which explains in our study the lack of robust corticosteroid action on the evoked release of GABA and glutamate either in the frontal cortex or the hippocampus. This somewhat contradicts the strong facilitation seen by Wang and Wang (2009) . In that study, the authors used fluorimetric detection of endogenously released glutamate with single 4-AP stimulation. Based on the ionic composition of their assay medium, we speculate that their glutamate release was more Na þ -and less Ca 2þ -dependent than ours, and that type of release can be better facilitated through the inhibition of hyperpolarizing K þ channels. Indeed, McRs are reportedly negatively associated with some forms of K þ channels in the hippocampus, increasing the likeliness of depolarization when a subtreshold stimulus reaches the glutamatergic terminal (Karst et al., 2005; Olijslagers et al., 2008) . A blockade of K þ channels also can explain how dexamethasone (1 mM) increased by~5% the resting release of glutamate in our assay. Another form of presynaptic priming is likely associated with the modulation of vesicular release: recent studies reported that stress and (pre)frontocortical GcR activation increase the readily releasable pool of glutamate (Popoli et al., 2011; Treccani et al., 2014) . Notably, this form of plasticity requires additional signals coincident with glucocorticoids in the living animal, because in the above study, acute stress ex vivo could increase the depolarizationinduced release of glutamate in the rat (pre)frontal cortex, but the in vitro application of the stress hormone corticosterone was not sufficient alone to achieve the same result (Treccani et al., 2014) .
In the present study we also asked if the activation of CB 1 Rs was that additional signal: although glucocorticoids directly did not modulate the release, a putative crosstalk between the added 4 or 15 min before S 2 at the concentrations of 0.1, 1 and 10 mM (as indicated right below the bars). Due to small effect amplitudes, bars correspond to the % changes in the S 2 /S 1 ratio, as compared to DMSO control taken as 100%, here represented with the 0% line. The discrepancy in the sample numbers for the dexamethasone (10 mM, 4 min) and corticosterone (10 mM, 4 min) data between panels (A) and (B) arises from that the effect of the two drugs on the resting release was also determined after 4 min perfusion in the 15-min-perfusion experiments, and this accounts for additional 6 data points. All data are mean ± S.E.M. of N ! 6 obsevations, as indicated under the bars; n.s., not significant. Consult also with Supplementary Fig. 1A . glutamate outflow is displayed upon 1 mM dexamethasone. Due to small effect amplitudes, bars correspond to the % changes in the S 2 /S 1 ratio, as compared to DMSO control taken as 100%, here represented with the 0% line. All data are mean ± S.E.M. of N ! 6 obsevations, as indicated under the bars; n.s., not significant, *P < 0.05. The discrepancy in the sample numbers for the dexamethasone (10 mM, 4 min) and corticosterone (10 mM, 4 min) data between panels (A) and (B) arises from that the effect of the two drugs on the resting release was also determined after 4 min perfusion in the 15-min-perfusion experiments, and this accounts for additional 6 data points. Consult also with Supplementary Fig. 1B . Fig. 7 . Pharmacology of presynaptic CB 1 Rs in (A) GABA-ergic and (B) glutamatergic nerve terminals of the frontal cortex. Due to small effect amplitudes, bars correspond to the % changes in the S 2 /S 1 ratio, as compared to DMSO control taken as 100%, here represented with the 0% line. For further details, see Materials and Methods as well as legends to Figs. 3 and 4. All data are mean ± S.E.M. of the indicated sample numbers after the bars (i.e. animal in duplicate). WT, wild-type mice; KO, CB 1 R KO mice. *P < 0.05, **P < 0.01, ***P < 0.001; n.s., not significant. corticosteroids and CB 1 Rs may occur presynaptically. This may be considered in two forms: either corticosteroids could prevent the CB 1 R from inhibiting the release of a neurotransmitter, or they could trigger an alternative second messenger system that facilitates transmitter release. Certainly, these assumptions are compelling because the endocannabinoid system has been reportedly recruited upon cerebral GcR receptor activation: a) the systemic injection of corticosterone rapidly increases endocannabinoid levels in limbic areas (Atsak et al., 2012; Hill et al., 2010) ; b) restraint stress causes a parallel increase of corticosterone levels in the plasma and endocannabinoid levels in the medial prefrontal cortex (Hill et al., 2011) ; c) application of corticosterone to prefrontocortical slices triggers endocannabinoid release to activate CB 1 Rs in GABA-ergic terminals contacting pyramidal cells (Hill et al., 2011) ; and d) dexamethasone and corticosterone rapidly suppress glutamatergic transmission via endocannabinoid release and retrograde signaling in the hypothalamic paraventricular nucleus (Di et al., 2003) . Our immunohistochemical data and the analysis of the subsynaptic localization of the receptors, together with the above references (a-d) support a testable arrangement in which the interaction between the two signaling systems is principally indirect, i.e. that glucocorticoids trigger endocannabinoid release in the post-synaptic compartment, which then activate juxtapositioned presynaptic CB 1 receptors via trans-synaptic retrograde endocannabinoid signaling, as postulated before (Hill and McEwen, 2009) .
Additionally, the CB 1 R is prone to interact with various receptors (Dalton and Howlett, 2012; Ferreira et al., 2015) , and frequently, the partner receptor either silences the CB 1 R-mediated inhibition of e.g. evoked glutamate release (Ferreira et al., 2015) , or the two interacting receptors may change their coupling to G s to facilitate cAMP accumulation and transmitter release (Glass and Felder, 1997) . As a result, a putative presynaptic CB 1 R-GcR heterodimer can have important consequences on the (patho)physiology of the prefrontal cortex.
Despite these cross-correlative data and the fact that both corticosteroid receptors and CB 1 Rs can modulate K þ channels, our pharmacological interrogation does not reveal a robust direct presynaptic interaction between these signaling systems. Besides the low presynaptic GcR density, this can be once again a question of sensitivity: the rapid inhibitory responses that the CB 1 R can trigger via either the closure of VGCCs or the opening of K þ channels apparently occur in separated pools of cortical nerve terminals, as revealed by a previous study (del Carmen Godino et al., 2007) . In that study, WIN55212-2 was much more effective in relative terms (up to 80%) to inhibit the low (5 mM K þ ) stimulus strength-evoked release via K þ channel opening. But by increasing the stimulus strength, VGCCs also get gradually recruited and become responsible for the majority of the net glutamate efflux (del Carmen Godino et al., 2007) . This prompts the hypothesis that under certain circumstances, McRs/GcRs and CB 1 Rs may be able to compete for the modulation of K þ channels in a subset of nerve terminals, but the overall outcome would be small. Altogether, we believe now that any direct rapid presynaptic neuromodulator action of corticosteroids could be better monitored in either patch clamp electrophysiology or in synaptosomal release experiments with greater sensitivity -e.g. via fluorimetric batch enzyme assay. As a drawback, the latter technique may narrow down the use of the assay for limited types of neurotransmitters such as glutamate. Furthermore, as this type of modulation requires minimal depolarization, we expect no robust rapid presynaptic response to corticosteroid treatment. The low presynaptic GcR density can indeed mask effect amplitudes in a batch assay via the dilution of the response by those nerve terminals that do not bear the receptor. For instance, in slice patch-clamp experiments, which allows observing unitary connections established by CB 1 R-bearing nerve terminals and hence no dilution of effect takes place, WIN55212-2 (2 mM) inhibits GABAergic synaptic transmission in the rat PFC by~35% (Hill et al., 2010) . Similarly, as shown by Lafourcade and colleagues (2007) , the highest CB 1 R-mediated inhibition of glutamatergic transmission is~40% in the mouse PFC. These effect amplitudes can be greatly diluted in a pool of synaptosomes by those terminals which do not bear CB 1 R. The frontal cortex shows layer cake-type CB 1 R staining: Layers IIeIII, Va and VI express high density of the CB 1 R while layers I, IV and Vb express little (Bodor et al., 2005; Ferreira et al., 2012; Marsicano and Lutz, 1999) . Nerve terminals from the CB 1 R-poor regions also contribute to [ 3 H]GABA and [ 14 C]glutamate release but will not respond to CB 1 R activation. The same may occur with the GcR and the McR. Hence, the best method to map how corticosteroids affect synaptic plasticity is still the use of electrophysiology in slices, but the drawback of that technique is that the measured response is frequently the resultant of changes in the tripartite synapse, protein synthesis, receptor trafficking and polysynaptic inputs (Maggio and Segal, 2012) .
Other models in which key findings on synaptic effects have been gathered are cell cultures. Studies on neural cell lines and primary cell cultures revealed the complex nature by which McRs and GcRs can trigger spatiotemporally distinct genomic and nongenomic responses, which can lead to changes in the expression and the clustering of pre-and post-synaptic proteins as well as to alterations in dendritic spine morphology (Chatterjee and Sikdar, 2014; Morsink et al., 2006; Sebastian et al., 2013) . Of note, dendritic degeneration also occurs in vivo, as documented in the layers ]glutamate, and the lack of dexamethasone effect is unchanged in the CB 1 R KO mice as compared to the WT littermates. Due to small effect amplitudes, bars correspond to the % changes in the S 2 /S 1 ratio, as compared to DMSO control taken as 100%, here represented with the 0% line. All data are mean ± S.E.M. of the indicated sample numbers after the bars (i.e. animal in duplicate). WT, wild-type mice; KO, CB 1 R KO mice. *P < 0.05, **P < 0.01, ***P < 0.001; n.s., not significant.
II/III of the medial PFC of rats after chronic (4-week) treatment with either dexamethasone or corticosterone (Cerqueira et al., 2007) .
In conclusion, despite that a part of our data is negative, our thorough analysis of the presynaptic action of corticosteroids contributes to the better understanding of the rapid mechanisms whereby stress can regulate brain functions, with relevance to neuropsychiatric disorders.
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